<DOC>
	<DOCNO>NCT00977873</DOCNO>
	<brief_summary>The study null hypothesis vitamin D supplementation influence time upper respiratory tract infection time moderate/severe exacerbation chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>Trial Vitamin D Supplementation Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Principal Medical record diagnosis COPD , emphysema bronchitis Postbronchodilator FEV1 / FVC &lt; 70 % postbronchodilator FEV1 / slow VC &lt; 70 % Postbronchodilator FEV1 &lt; 80 % predict Age ≥ 40 year day first dose IMP Smoking history ≥ 15 packyears If woman childbearing potential , sexually abstinent negative pregnancy test within 7 day recruitment agree use reliable form contraception complete study Able give write informed consent participate Current diagnosis asthma Known clinically significant bronchiectasis Known sarcoidosis , hyperparathyroidism , nephrolithiasis , active tuberculosis , vitamin D intolerance , liver failure , renal failure , terminal illness , lymphoma malignancy remission ≥ 3 year Taking benzothiadiazine derivative , cardiac glycoside , carbamazepine , phenobarbital , phenytoin primidone Taking dietary supplement topical preparation contain vitamin D 2 month first dose IMP Treatment investigational medical product device 4 month first dose IMP Breastfeeding , pregnant planning pregnancy Baseline correct serum calcium &gt; 2.65 mmol/L Baseline serum creatinine &gt; 125 micromol/L</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>